In relation to the expression of UBE2C in metastatic PRAD based on androgen receptor (AR) amplification and ERG fusion, there is no significance difference compared to condition without these changes (Table 1 and Figure S2 panel 1H). The gene discussed is AR; the disease is prostate adenocarcinoma.